Amid the worsening effect of prolonged COVID, the U. S. National Institutes of Health’s billion-dollar RECOVER initiative is a major contributor. The U. S. Food and Drug Administration has chosen the antiviral drug Paxlovid from Pfizer Inc. as the first remedy he will test on patients with prolonged COVID.
According to some reports, the long COVID complex comes to have more than two hundred symptoms ranging from exhaustion and cognitive impairment to pain, fever and central palpitations that can last for months or even years after a COVID-19 infection.
According to the main points of the study, the randomized placebo-controlled trial will test either the Pfizer remedy or a placebo on 1,700 volunteers over the age of 18, according to Reuters.
The Duke Clinical Research Institute is overseeing the study, which is expected to begin Jan. 1.
The trial will investigate a leading theory about the cause of prolonged COVID, according to which fragments of the virus persist in the tissues of some individuals, prolonged symptoms.
Patients in several case studies reported improvement in their symptoms after taking Pfizer’s antiviral treatment, and several doctors called for the drug to be studied scientifically rigorously in long-term COVID patients. Read more
Paxlovid, which combines a new Pfizer tablet with the old antiviral ritonavir, was reportedly recently cleared for use in the early days of a COVID infection to prevent severe illness in high-risk patients.
READ ALSO| Updated evidence on the blood clotting side effect of Covid Jab: study
Long-term prevalence estimates of COVID diversity of 5% to 50% of other people who have had a COVID-19 infection. It affects others who have had mild or severe COVID-19, including children, and can be severe enough to prevent others from working.
(With contributions from Reuters)